Atherosclerosis Process

Category	Biology
Also known as	Atherosclerotic Plaque, Arterial Plaque Formation, Atherogenesis
Last updated	2026-04-14
Reading time	5 min read
Tags	cardiovascularatherosclerosisinflammationcholesterolvascular-disease

Overview

Atherosclerosis is a chronic inflammatory disease of medium and large arteries characterized by the progressive accumulation of lipids, immune cells, and fibrous material within the arterial wall. Once considered a simple plumbing problem of cholesterol deposition, atherosclerosis is now understood to be an immunological process driven by endothelial dysfunction, oxidized lipoprotein retention, and maladaptive inflammatory responses.

Atherosclerosis develops over decades, beginning with subtle endothelial changes in childhood and progressing through fatty streak formation, fibroinflammatory plaque development, and eventually plaque rupture or erosion, which triggers acute thrombotic events such as myocardial infarction and ischemic stroke. It is the leading cause of death worldwide, and its prevention and treatment are central goals of cardiovascular medicine.

How It Works

Atherosclerosis begins with endothelial activation at sites of disturbed blood flow, particularly arterial branch points and curvatures where turbulent or oscillatory shear stress replaces the protective laminar flow pattern. Disturbed flow reduces endothelial nitric oxide production, increases oxidative stress, and activates NF-kB signaling, priming the endothelium for inflammatory cell recruitment.

Lipoprotein retention is the initiating event that converts endothelial activation into disease. Low-density lipoprotein (LDL) particles infiltrate the intima and become trapped by binding to extracellular matrix proteoglycans. Retained LDL undergoes oxidative modification by reactive oxygen species, producing oxidized LDL (oxLDL), which is both a potent pro-inflammatory stimulus and a substrate for macrophage uptake through scavenger receptors.

Monocyte recruitment follows endothelial activation. Inflammatory cytokines and oxLDL upregulate endothelial adhesion molecules (VCAM-1, ICAM-1), capturing circulating monocytes that transmigrate into the intima and differentiate into macrophages. These macrophages engulf oxLDL through scavenger receptors (SR-A, CD36) without the negative feedback that limits receptor-mediated LDL uptake. The resulting lipid-engorged cells, called foam cells, form the fatty streak, the earliest visible atherosclerotic lesion.

As the lesion progresses, foam cells die and release their lipid contents, forming a necrotic core of extracellular lipid, cholesterol crystals, and cellular debris. Smooth muscle cells migrate from the media into the intima and produce collagen and other matrix proteins, forming a fibrous cap over the necrotic core. T-cells and other adaptive immune cells infiltrate the plaque, perpetuating the inflammatory cycle through interferon-gamma and other cytokine production.

Plaque vulnerability depends on the balance between fibrous cap stability and inflammatory degradation. Stable plaques have thick fibrous caps and small necrotic cores; vulnerable plaques have thin caps, large necrotic cores, and active inflammation. Matrix metalloproteinases (MMPs) secreted by activated macrophages degrade collagen in the fibrous cap, predisposing to plaque rupture. When the cap ruptures, the thrombogenic necrotic core is exposed to circulating blood, triggering the coagulation cascade and acute thrombus formation.

Key Components

Oxidized LDL: Modified lipoprotein that drives foam cell formation, endothelial activation, and immune cell recruitment.
Foam Cells: Lipid-laden macrophages that are the cellular hallmark of atherosclerosis.
Fibrous Cap: Collagen-rich structure overlying the necrotic core. Its integrity determines plaque stability.
Necrotic Core: Accumulation of dead foam cells, extracellular lipid, and cholesterol crystals.
Matrix Metalloproteinases: Enzymes that degrade extracellular matrix, weakening the fibrous cap and promoting plaque rupture.
Vascular Smooth Muscle Cells: Migrate into the intima and produce matrix proteins that stabilize the plaque. Their apoptosis reduces cap stability.

Peptide Connections

The inflammatory signaling that drives atherosclerosis involves multiple peptide mediators. Chemokines (MCP-1/CCL2, fractalkine/CX3CL1) are small peptide chemoattractants that recruit monocytes and T-cells into the developing plaque. Cytokines including IL-1beta, TNF-alpha, and interferon-gamma perpetuate the inflammatory cycle. The NF-kB pathway, a master regulator of inflammatory gene expression, coordinates the endothelial response to atherogenic stimuli.
Endothelial function is intimately connected to atherosclerosis through the nitric oxide system. NO suppresses key atherogenic processes including LDL oxidation, monocyte adhesion, smooth muscle proliferation, and platelet aggregation. Peptides that support endothelial health and NO bioavailability, such as BPC-157, are of interest for their potential to address the endothelial dysfunction that initiates and perpetuates atherogenesis.
Natriuretic peptides (ANP, BNP) have demonstrated anti-inflammatory and anti-proliferative effects on vascular smooth muscle cells in experimental models, suggesting these endogenous peptide systems may provide some protection against atherosclerotic progression. BNP levels are used clinically to assess the cardiac consequences of atherosclerotic coronary disease.

Clinical Significance

Atherosclerosis is responsible for the majority of cardiovascular deaths through myocardial infarction, ischemic stroke, and peripheral artery disease. Risk factor modification (LDL lowering, blood pressure control, smoking cessation, glucose management) targets the drivers of atherogenesis. Statin therapy reduces LDL levels and has anti-inflammatory effects that stabilize existing plaques.

The CANTOS trial demonstrated that targeted anti-inflammatory therapy (canakinumab, an anti-IL-1beta antibody) reduces cardiovascular events independent of LDL lowering, confirming the causal role of inflammation in atherosclerotic complications. Colchicine, an anti-inflammatory agent, has also shown cardiovascular benefit. These findings validate the inflammatory model of atherosclerosis and support the development of anti-inflammatory strategies, including peptide-based approaches, for cardiovascular risk reduction.